Moreover, improved anti-tumor activity was observed particularly upon pre-treatment of AML cells with all-trans retinoic acid, which promoted upregulation of CD38 on malignant cells and hence increased sensitivity toward CD38-CAR-NK treatment [93]. The gene discussed is CD38; the disease is acute myeloid leukemia.